BrightGene Bio-Medical Technology Co

BrightGene Bio-Medical Technology Co EBIT Growth

The Year-over-Year EBIT Growth of BrightGene Bio-Medical Technology Co (688166.SS) as of Nov 22, 2026 is -56.07 %. In the previous year, Year-over-Year EBIT Growth was -1.09 % — a change of 5,022.49% (lower).

EBIT Growth

-56.07 %

YoY

5,022.49%

Last updated:

Year-over-Year EBIT Growth of BrightGene Bio-Medical Technology Co is 2025 -56.07 % . Year-over-Year EBIT Growth of BrightGene Bio-Medical Technology Co was 2024 -1.09 % . It decreases by 5,022.49% lower compared to the previous year.

The BrightGene Bio-Medical Technology Co EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2018
53.48 CNY
Jan 1, 2019
44.79 CNY
Jan 1, 2020
65.73 CNY
Jan 1, 2021
31.76 CNY
Jan 1, 2022
-3.55 CNY
Jan 1, 2023
-4.18 CNY
Jan 1, 2024
-1.09 CNY
Jan 1, 2025
-56.07 CNY
The BrightGene Bio-Medical Technology Co EBIT Growth history
YEAREBIT GrowthYoY
-56.07 %+5,022.49%
-1.09 %-73.80%
-4.18 %+17.66%
-3.55 %-111.18%
31.76 %-51.69%
65.73 %+46.76%
44.79 %-16.26%
53.48 %-73.62%
202.72 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BrightGene Bio-Medical Technology Co Stock analysis

What does BrightGene Bio-Medical Technology Co do? BrightGene Bio-Medical Technology Co., Ltd. generates revenue by researching, developing, and manufacturing biopharmaceuticals, medicines, and special generic active pharmaceutical ingredients and finished dosage forms. The company's product portfolio centers on antifungal, antiviral, and immunosuppressive APIs, alongside other APIs and preparations. Its generic drug offerings specifically include entecavir, caspofungin, micafungin, posaconazole, everolimus, and fondaparinux sodium. The firm sells these products to customers in both domestic and overseas markets. By leveraging its capabilities in producing essential active pharmaceutical ingredients and finished dosage forms, the company serves the broader pharmaceutical sector through its established manufacturing and research operations. BrightGene Bio-Medical Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BrightGene Bio-Medical Technology Co stock

Year-over-Year EBIT Growth of BrightGene Bio-Medical Technology Co is -56.07 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth BrightGene Bio-Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's BrightGene Bio-Medical Technology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — BrightGene Bio-Medical Technology Co

All Key Metrics — BrightGene Bio-Medical Technology Co